Use of Terahertz-Raman Spectroscopy to Determine Solubility of the Crystalline Active Pharmaceutical Ingredient in Polymeric Matrices during Hot Melt Extrusion.
API−polymer solubility
Terahertz-Raman spectroscopy
amorphous solid dispersion
stability prediction
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
07 10 2019
07 10 2019
Historique:
pubmed:
23
8
2019
medline:
18
6
2020
entrez:
23
8
2019
Statut:
ppublish
Résumé
Polymer-based amorphous solid dispersions (ASDs) comprise one of the most promising formulation strategies devised to improve the oral bioavailability of poorly water-soluble drugs. Exploitation of such systems in marketed products has been limited because of poor understanding of physical stability. The internal disordered structure and increased free energy provide a thermodynamic driving force for phase separation and recrystallization, which can compromise therapeutic efficacy and limit product shelf life. A primary concern in the development of stable ASDs is the solubility of the drug in the polymeric carrier, but there is a scarcity of reliable analytical techniques for its determination. In this work, terahertz (THz) Raman spectroscopy was introduced as a novel empirical approach to determine the saturated solubility of crystalline active pharmaceutical ingredient (API) in polymeric matrices directly during hot melt extrusion. The solubility of a model compound, paracetamol, in two polymer systems, Affinisol 15LV (HPMC) and Plasdone S630 (copovidone), was determined by monitoring the API structural phase transitions from crystalline to amorphous as an excess of crystalline drug dissolved in the polymeric matrix. THz-Raman results enabled construction of solubility phase diagrams and highlighted significant differences in the solubilization capacity of the two polymer systems. The maximum stable API-load was 20 wt % for Affinisol 15LV and 40 wt % for Plasdone S630. Differential scanning calorimetry and XRPD studies corroborated these results. This approach has demonstrated a novel capability to provide real-time API-polymer phase equilibria data in a manufacturing relevant environment and promising potential to predict solid-state solubility and physical stability of ASDs.
Identifiants
pubmed: 31436094
doi: 10.1021/acs.molpharmaceut.9b00703
pmc: PMC6785800
doi:
Substances chimiques
Pharmaceutic Aids
0
Polymers
0
Pyrrolidines
0
Vinyl Compounds
0
poly(vinylpyrrolidone-co-vinyl-acetate)
0
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4361-4371Références
Mol Pharm. 2015 Aug 3;12(8):2823-33
pubmed: 26107071
Mol Pharm. 2015 Sep 8;12(9):3408-19
pubmed: 26214347
J Pharm Sci. 2017 Apr;106(4):1042-1050
pubmed: 27988162
J Pharm Sci. 2014 Sep;103(9):2847-2858
pubmed: 24634063
Mol Pharm. 2017 Jan 3;14(1):183-192
pubmed: 28043131
J Pharm Sci. 2010 Sep;99(9):4023-31
pubmed: 20607809
Int J Pharm. 2016 Feb 29;499(1-2):175-185
pubmed: 26768722
J Phys Chem A. 2012 Oct 25;116(42):10359-64
pubmed: 23039044
Eur J Pharm Biopharm. 2018 Mar;124:147-157
pubmed: 29269154
Chem Commun (Camb). 2009 Jun 14;(22):3181-3
pubmed: 19587906
Mol Pharm. 2013 Jan 7;10(1):236-48
pubmed: 23110477
Int J Pharm. 2018 Apr 5;540(1-2):98-105
pubmed: 29425764
Drug Discov Today. 2007 Dec;12(23-24):1068-75
pubmed: 18061887
Int J Pharm. 2019 Apr 20;561:324-334
pubmed: 30858115
Carbohydr Polym. 2018 Feb 15;182:149-158
pubmed: 29279109
Pharm Res. 2009 Apr;26(4):855-64
pubmed: 19052850
Int J Pharm. 2018 Jan 15;535(1-2):245-252
pubmed: 29133204
Pharm Res. 2010 May;27(5):775-85
pubmed: 20195707
Drug Dev Ind Pharm. 2015 Jun;41(6):875-87
pubmed: 25342479
Pharm Res. 2018 Apr 23;35(6):125
pubmed: 29687226
J Pharm Sci. 2018 Jan;107(1):362-371
pubmed: 28989021
Eur J Pharm Biopharm. 2015 Oct;96:237-46
pubmed: 26247119
Mol Pharm. 2013 Feb 4;10(2):560-6
pubmed: 23253068
Int J Pharm. 2014 Sep 10;472(1-2):241-7
pubmed: 24968139
J Pharm Sci. 2011 Aug;100(8):3196-3207
pubmed: 21416468
Eur J Pharm Biopharm. 2008 May;69(1):364-71
pubmed: 18036792
Mol Pharm. 2012 Jun 4;9(6):1544-58
pubmed: 22540366
Int J Pharm. 2018 Mar 1;538(1-2):243-249
pubmed: 29341914
Mol Pharm. 2014 Jul 7;11(7):2453-65
pubmed: 24897345
Mol Pharm. 2017 Jan 3;14(1):157-171
pubmed: 28043133
J Pharm Sci. 2010 Jul;99(7):2941-7
pubmed: 20127825
Eur J Pharm Biopharm. 2014 Nov;88(3):897-908
pubmed: 25111184
Eur J Pharm Biopharm. 2015 Aug;94:352-62
pubmed: 26117187
Mol Pharm. 2011 Apr 4;8(2):532-42
pubmed: 21323367
J Pharm Sci. 2017 Jan;106(1):5-27
pubmed: 27372552
Appl Spectrosc. 2015 Nov;69(11):1217-28
pubmed: 26647045
Eur J Pharm Biopharm. 2019 Aug;141:149-160
pubmed: 31132400
Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):162-7
pubmed: 20002064
Sci Rep. 2017 Apr 11;7:46367
pubmed: 28397829
Int J Pharm. 2018 Dec 20;553(1-2):454-466
pubmed: 30393199
Pharm Res. 2006 Oct;23(10):2417-26
pubmed: 16933098